Amelia Bourdeau and Tor Vollalokken joins Exante Data

Dear Friends and Colleagues,

We are pleased to announced two senior additions to the Exante Data team, which will help us build analytical depth and expand our client reach globally.

We are pleased that Amelia Bourdeau is joining Exante to lead new initiatives on external communication. Amelia has a unique background that straddles both market strategy and communication. Her unique skills mix allows her to deliver complex analytical content to global audiences. 

Amelia has 17 years of experience in financial markets.  She started her career as a research analyst at the Federal Reserve Board, and held prominent strategist roles at Deutsche Bank, UBS as well as on the buy-side (macro hedge funds). She also has experience in institutional sales roles (Westpac, Unicredit). 

She has a B.A. in Economics and Political Science magna cum laude from Amherst College and a M.S. in Journalism from Columbia University’s Graduate School of Journalism. Amelia has been a regular contributor on CNBC and can be seen frequently on several financial media outlets. 

 

We are also pleased to announce that Tor Vollalokken has joined Exante Data as Senior Advisor this month. Tor is based in Barcelona and Oslo and will be a key client contact point with respect to the Nordic region.

Tor spent the first 15 years of his professional life in real money (DnB, Oslo and London) and thereafter as a Consultant and Advisor to macro hedge funds, sovereigns, family offices and corporates within energy sectors.

We have known Tor for 10 years. We think his analytical depth and creativity is unparallelled, and his long-standing FX activity makes him ideally placed to represent Exante Date in the Nordic and broader European region, as well as function as a new resource to Exante Data clients globally.

 

Jens Nordvig
Founder and CEO
Exante Data Inc.

Exante Data © 2024. All rights reserved. Personal Data Usage Policy


This site is provided for informational purposes only.  The information included in this site should not be used as the sole basis for making a decision as to whether or not to invest in any particular security. In making an investment decision, you must rely on your own examination of the securities and the terms of the offering. You should not construe the contents of these materials as legal, tax, investment or other advice, or a recommendation to purchase or sell any particular security.

The information included in this site is based upon information reasonably available to Exante as of the date noted herein. Furthermore, the information included in this site has been obtained from sources that Exante believes to be reliable; however, these sources cannot be guaranteed as to their accuracy or completeness. Information contained in this site does not purport to be complete, nor does Exante undertake any duty to update the information set forth herein. No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information contained herein, by Exante, its members, partners or employees, and no liability is accepted by such persons for the accuracy or completeness of any such information.

This site contains certain “forward-looking statements,” which may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “potential,” “outlook,” “forecast,” “plan” and other similar terms. Examples of forward-looking statements include, but are not limited to, estimates with respect to financial condition, results of operations, and success or lack of success of certain investment strategy. All are subject to various factors, including, but not limited to, general and local economic conditions, changing levels of competition within certain industries and markets, changes in interest rates, changes in legislation or regulation, and other economic, competitive, governmental, regulatory and technological factors affecting the operations of the companies identified herein, any or all of which could cause actual results to differ materially from projected results.